GENENTA SCIENCE S.P.A.

Genenta Secures Approval for Innovative Trial for Metastatic Renal Cell Cancer

02 Oct 2024 06:30:00 By Nasdaq GlobeNewswire

Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider

06 May 2024 06:25:00 By Nasdaq GlobeNewswire

Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors

08 Feb 2024 05:00:00 By Nasdaq GlobeNewswire

Genenta to Present at Upcoming Scientific and Investor Conferences

06 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments

28 Jul 2023 03:00:00 By Nasdaq GlobeNewswire

The European Commission Grants Orphan Drug Designation to Temferon™ for Treatment of Glioma

29 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

Genenta to Provide Update on Lead Product Temferon™

16 May 2023 07:00:00 By Nasdaq GlobeNewswire

Genenta Announces Fiscal Year 2022 Financial Results and Annual Report on Form 20-F Filing

26 Apr 2023 07:00:00 By Nasdaq GlobeNewswire

Genenta Announces Extension of License Agreement with Ospedale San Raffaele to All Solid Tumor Indications

03 Apr 2023 07:00:00 By Nasdaq GlobeNewswire

FDA Grants Orphan Drug Designation to Temferon for Treatment of Glioblastoma Multiforme

02 Mar 2023 06:45:00 By Nasdaq GlobeNewswire

Genenta Science and AGC Biologics Enter Development and Manufacturing Service Agreement

07 Feb 2023 07:00:01 By Nasdaq GlobeNewswire

Genenta Update at SITC22 Indicates Potential for Anti-Tumor Immune System Reset after Temferon™ Treatment in Glioblastoma Patients

07 Nov 2022 08:05:00 By Nasdaq GlobeNewswire

Genenta Provides First Half 2022 Business Update and Financial Results

24 Oct 2022 07:30:00 By Nasdaq GlobeNewswire

Genenta to Present at Upcoming Scientific and Investor Conferences

05 Oct 2022 08:05:00 By Nasdaq GlobeNewswire

Genenta to Present at Upcoming Investor Conferences

07 Sep 2022 07:00:01 By Nasdaq GlobeNewswire

AmCham Italy and Genenta Science Announce the Bowling Green Bull Initiative

25 Jul 2022 06:00:00 By Nasdaq GlobeNewswire

Genenta to Present at Upcoming Scientific Congresses ASGCT, BTM, ASCO and EHA

13 May 2022 07:30:00 By Nasdaq GlobeNewswire

Genenta Appoints Industry Veteran Tim Obara as Head of Business Development

09 May 2022 07:30:00 By Nasdaq GlobeNewswire

Genenta Files Annual Report on Form 20-F for Fiscal Year 2021

04 May 2022 16:30:00 By Nasdaq GlobeNewswire

Genenta Progresses to Higher Dosing Cohort in Temferon™ Phase 1/2a Clinical Trial in Glioblastoma Multiforme

04 May 2022 07:30:00 By Nasdaq GlobeNewswire